Role of rosuvastatin in the primary and secondary prevention of cardiovascular disease
- Authors: Yalymov A.A1, Shekhyan G.G1, Shchikota A.M1, Zadionchenko V.S1
-
Affiliations:
- A.I.Evdokimov Moscow State University of Medicine and Dentistry of the Ministry of Health of the Russian Federation
- Issue: Vol 18, No 5 (2016)
- Pages: 70-76
- Section: Articles
- URL: https://bakhtiniada.ru/2075-1753/article/view/94481
- ID: 94481
Cite item
Full Text
Abstract
Full Text
##article.viewOnOriginalSite##About the authors
A. A Yalymov
A.I.Evdokimov Moscow State University of Medicine and Dentistry of the Ministry of Health of the Russian Federation
Email: ayalymov@gmail.com
канд. мед. наук, доц. каф. поликлинической терапии ГБОУ ВПО МГМСУ им. А.И.Евдокимова 127473, Russian Federation, Moscow, ul. Delegatskaia, d. 20, str. 1
G. G Shekhyan
A.I.Evdokimov Moscow State University of Medicine and Dentistry of the Ministry of Health of the Russian Federationканд. мед. наук, доц. каф. поликлинической терапии ГБОУ ВПО МГМСУ им. А.И.Евдокимова 127473, Russian Federation, Moscow, ul. Delegatskaia, d. 20, str. 1
A. M Shchikota
A.I.Evdokimov Moscow State University of Medicine and Dentistry of the Ministry of Health of the Russian Federationканд. мед. наук, доц. каф. поликлинической терапии ГБОУ ВПО МГМСУ. им. А.И.Евдокимова 127473, Russian Federation, Moscow, ul. Delegatskaia, d. 20, str. 1
V. S Zadionchenko
A.I.Evdokimov Moscow State University of Medicine and Dentistry of the Ministry of Health of the Russian Federationд-р мед. наук, проф. каф. поликлинической терапии ГБОУ ВПО МГМСУ им. А.И.Евдокимова, засл. деят. науки РФ 127473, Russian Federation, Moscow, ul. Delegatskaia, d. 20, str. 1
References
- Задионченко В.С., Шахрай Н.Б., Шехян Г.Г. и др. Особенности фармакологических и клинических свойств розувастатина. Рус. мед. журн. 2011; 19 (12; 406): 772-8.
- Задионченко В.С., Шехян Г.Г., Шахрай Н.Б. и др. Влияние розувастатина на липидный обмен, микроциркуляцию и показатели центральной гемодинамики у больных с острым коронарным синдромом // Consilium Medicum. 2011; 13 (5): 85-9.
- Рекомендации Комитета экспертов Всероссийского научного общества кардиологов. Диагностика и коррекция нарушений липидного обмена с целью профилактики и лечения атеросклероза (IV пересмотр). Кардиоваск. терапия и профилактика. 2009; 8 (6).
- Рекомендации Комитета экспертов Всероссийского научного общества кардиологов и Нацинального научного общества «Кардиоваскулярная профилактика и реабилитация». Кардиоваскулярная профилактика. Кардиоваск. терапия и профилактика. 2011; 10 (6), Прил. 2.
- Бойцов С.А., Сусеков А.В., Аронов Д.М. и др. Актуальные вопросы терапии статинами в клинической практике. Совещание совета экспертов. Атеросклероз и дислипидемии. 2011; 1: 65-6.
- Berne C, Siewert-Delle A; and URANUS study investigators. Comparison of rosuvastatin and atorvastatin for lipid lowering in patients with type 2 diabetes mellitus: results from the URANUS study. Cardiovasc. Diabetol 2005; 4: 7.
- Betteridge D.J, Gibson J.M, Sager P.T. Comparison of effectiveness of rosuvastatin versus atorvastatin on the achievement of combined C-reactive protein (<2 mg/l) and low - density lipoprotein cholesterol (<70 mg/dl) targets in patients with type 2 diabetes mellitus (from the ANDROMEDA study). Am J Cardiol 2007; 100: 1245-8.
- Binbrek A.S, Elis A, Al-Zaibag M et al. Rosuvastatin versus atorvastatin in achieving lipid goals in patients at high risk for cardiovascular disease in clinical practice: a randomized, open - label, parallel - group, multicenter study (DISCOVERY Alpha Study). Curr Ther Res Clin Exp 2006; 67: 21-43.
- Clearfield M, Kallend D, Palmer M. Efficacy and safety of rosuvastatin 10 mg versus atorvastatin 20 mg: results of the PULSAR study. Atheroscler (Suppl.) 2005; 6: 104.
- Danchin N, Chadarevian R, Gayet J-L et al. Compared with atorvastatin at a dose of 10 mg per day rosuvastatin was more effective to reach an LDL goal of <1.00 g/l in high cardiovascular risk patients (ARIANE study). Ann Cardiol Angiol (Paris) 2007; 56: 82-7.
- Faergeman O, Hill L, Windler E et al. Efficacy and tolerability of rosuvastatin and atorvastatin when force - titrated in patients with primary hypercholesterolemia. Results from the ECLIPSE Study. Cardiol 2008; 111: 219-28.
- Jones P.H, Davidson M.H, Stein E.A et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR trial). Am J Cardiol 2003; 92: 152-60.
- Lablanche J.M, Danchin N, Farnier M et al. Effects of rosuvastatin and atorvastatin on the apolipoprotein B/apolipoprotein A-1 ratio in patients with an acute coronary syndrome: The CENTAURUS trial design. Arch Cardiovasc. Dis 2008; 101: 399-406.
- Ridker P.M, Mac Fadyen J, Cressman M et al. Efficacy of rosuvastatin among men and women with moderate chronic kidney disease and elevated high - sensitivity C-reactive protein: a secondary analysis from the JUPITER (Justification for the Use of Statins in Prevention an Intervention Trial Evaluating Rosuvastatin) trial. J Am Coll Cardiol 2010; 55: 1266-73.
- Schuster H, Barter P.J, Stender S et al. Effects of switching statins on achievement of lipid goals: Measuring Effective Reductions in Cholesterol Using Rosuvastatin therapy (MERCURY I) study. Am Heart J 2004; 147: 705-12.
- Schuster H. The GALAXY Program: an update on studies investigating efficacy and tolerability of rosuvastatin for reducing cardiovascular risk. Expert Rev Cardiovasc Ther 2007; 5 (2): 177-93.
- Soeda T, Uemura S, Okayama S et al. Intensive Lipid-Lowering Therapy With Rosuvastatin Stabilizes Lipid-Rich Coronary Plaques (Evaluation Using Dual-Source Computed Tomography). Circ J 2011; 75: 2621-7.
- Erbs S, Beck E.B, Linke A et al. High - dose rosuvastatin in chronic heart failure promotes vasculogenesis, corrects endothelial function, and improves cardiac remodeling - results from a randomized, double - blind, and placebo - controlled study. Int J Cardiol 2011; 7, 146 (1): 56-63.
Supplementary files
